PPT-Boceprevir

Author : aaron | Published Date : 2017-09-03

with PEG RBV in Genotype 1 SPRINT 1 Phase 2 Treatment Naïve Kwo PY et al Lancet 201037670516 Source Kwo PY et al Lancet 201037670516 Boceprevir for TreatmentNaïve

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "Boceprevir" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Boceprevir: Transcript

with PEG RBV in Genotype 1 SPRINT 1 Phase 2 Treatment Naïve Kwo PY et al Lancet 201037670516 Source Kwo PY et al Lancet 201037670516 Boceprevir for TreatmentNaïve HCV Genotype 1. for Patients with Prior Failure to PEG + RIB. PROVIDE. Phase . 3. Treatment. . Experienced. Vierling. JM, . et al. . J . Hepatol. . 2013;Dec 19 [. Epub. ahead of print].. Source: . Vierling. . JM, et al. J . RESPOND-2. Phase . 3. Treatment. . Experienced. Bacon BR, et al. N . Engl. J Med. 2011;364:1207-17.. Source: . Bacon BR, et al. N Engl J Med. 2011;364:1207-17.. Boceprevir for Retreatment of HCV Genotype 1 Infection . Marie-Louise Vachon, MD, . MSc. Division of . Infectious. . Diseases. Centre Hospitalier Universitaire de Québec. Management of HCV . in Co-Infected Patients. Prevention and counselling. Baseline laboratory testing. Morris Sherman MD . BCh. PhD FRCP(C) . Associate Professor of Medicine. University of Toronto. Protease Inhibitors . in Chronic . Hepatitis C:. An . Update. Chapter 2. – Important Hepatitis C Protease Inhibitor Drug Interactions in Mono and HIV . thalassaemia. . Where . are we now?. Telaprevir . and . boceprevir. harbingers . of important . treatment advance. Improved response rates . observed : . naive . and . experienced patients. SVR > 70. Morris Sherman MD . BCh. PhD FRCP(C) . Associate Professor of Medicine. University of Toronto. Protease Inhibitors . in Chronic . Hepatitis C:. An . Update. COMPLETE SLIDE DECK (Chapters 1 – 6). November 2012. Morris Sherman MD . BCh. PhD FRCP(C) . Associate Professor of Medicine. University of Toronto. Protease Inhibitors . in Chronic . Hepatitis C:. An . Update. Chapter 5. – Case Study: Cirrhosis. November 2012. Morris Sherman MD . BCh. PhD FRCP(C) . Associate Professor of Medicine. University of Toronto. Protease Inhibitors . in Chronic . Hepatitis C:. An . Update. Chapter 4. – Case Study: Treatment Naive. SPRINT-2. Phase 3, Treatment . Naive. Treatment. . Naïve. Source: . Poordad F, . et al. . N Engl J Med. 2011;364:1195-206.. Boceprevir . for Treatment-Naïve HCV Genotype 1. SPRINT. -2 Trial: Study Design. Créteil, France. Paris, 30 January 2012. Triple therapy today:. Safety management in clinical practice. Telaprevir. placebo-controlled Phase II/III studies: . summary of AEs during . telaprevir. /placebo phase. Mark Sulkowski, . MD. Professor of Medicine. Medical Director, Viral Hepatitis Center . Johns Hopkins University. Baltimore Maryland USA. Liver disease is the second leading specific causes of death amongst HIV-positive individuals in the D:A:D study. in Hepatitis C . Paris . Februari. 2012. Ola . Weiland. Karolinska Institutet. Stockholm, Sweden. New major adverse events with PIs. . Exanthema for TVR. . Prolonged anemia with BOC. Telaprevir. Illuminate study. SPRINT. -1. Phase . 2. Treatment. . Naïve. Kwo. PY, et al. Lancet. 2010;376:705-16.. Source: . Kwo PY, et al. Lancet. 2010;376:705-16. .. Boceprevir . for Treatment-Naïve HCV Genotype 1. SPRINT.

Download Document

Here is the link to download the presentation.
"Boceprevir"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.